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Psychiatry is a human science and its subject matter is the individual’s psychic reality which defies the degree of 
certainty and validity required of the discourse in natural sciences. However, modern psychiatry, as we know it, in the 
21st century has moved from understanding the psychogenic cause of a symptom to a medical model of controlling 
and manipulating symptoms. An important reason for this shift was the increasing awareness that some medications 
(lithium carbonate, antipsychotics, antidepressants, anxiolytics) were of benefit to certain kinds of disorders, and the 
ongoing research in this area held a promise for better and more effective medications that could target many other 
mental disorders. Equally important was the dissatisfaction and conflict within the profession, as well as the attacks, 
in the 1950’s, from the antipsychiatry movement that challenged the arbitrariness of psychiatric diagnosis which lacked 
a pathophysiologic explanation for the illness. An indication of the American Psychiatric Association’s (APA) struggle to 
develop a credible classification system of psychiatric disorders is best reflected in the history of the Diagnostic Statistical 
Manual (DSM). This manual was first published in 1952, with subsequent revisions, the latest being the publication of 
DSM-5, in 2013. Until the 1970’s the manuals (DSM-I and DSM-II) were conceived on a biopsychosocial model with 
a psychodynamic tilt influenced by Freud’s theory of personality development and intrapsychic conflict, as well as 
Meyer’s psychosocial model, which downplayed psychiatric disorders as discrete, specific pathological entities. This 
model had a significant impact in teaching and clinical practice with individual psychotherapy becoming an essential 
feature of psychiatry. However the shortcoming of this approach was that it lacked a clear demarcation between the 
mentally healthy and sick; this lead to questions about the status and legitimacy of psychiatry as a medical science. 
Added to the grave doubts about the validity and reliability of psychiatric diagnosis was the embarrassment when in the 
early 1970’s the gay rights movement lobbied against homosexuality being labeled as a disorder in DSM-II, which was 
later excluded from DSM III published in 1980. So the removal of a disorder was based on political pressure, rather 
than scientific research. DSM-III (followed by DSM-III- R, 1989) which was a significant turning point in the history of 
psychiatry in USA, adopted a descriptive, nosological approach which could be supported by research findings that lent 
greater reliability and validity to psychiatric constructs. Assessment through description of symptoms which were 
publicly visible was stressed over psychological etiology which by its very nature was private and invisible. This bold and 
creditable step by the APA was not free from criticisms, many of which were warranted. A most vocal critic of DSM-III-R, 
Dr. Paula Caplan a clinical and research psychologist, and a human rights advocate, forwarded a trenchant argument 
against the inclusion of diagnostic labels, such as Self-Defeating Personality Disorder (SDPD) and Premenstrual 
Dysphoric Disorder (PMDD). Both these disorders were applicable to a majority of women. The former (SDPD), 
facetiously referred to as “good wife syndrome”, included characteristics such a putting needs of others ahead of one’s 
own, feeling unappreciated etc. Interestingly, this “portrait” of SDPD is most germane to the accepted and desirable 
gender role for Pakistani women as well. The latter’s (PMDD) diagnostic features consist of “bloating” breast tender-
ness coupled with irritability, fatigue, being “on edge” etc. Dr. Caplan questioned the scientific basis of inclusion of 
PMDD in a psychiatric manual, pointing out that it is just a fancy name for PMS. In lieu of the scathing criticism from 
feminists, the two diagnoses were not included in the main text of DSM-III-R and DSM-IV-TM (2004) but were instead 
placed in an appendix titled “Diagnostic Categories Needing Further Study.” The publication of DSM-5 in 2013, nine 
years after DSM-IV-TM was awaited with much anticipation. Surprisingly, mental health professionals expressed 
concerns while DSM-5 was in the making. Most of these concerns were around newly introduced categories and the 
lowering of thresholds for many disorders which would invariably lead to over diagnosis of the existing disorders. Allen 
Frances, who chaired the task force of DSM-IV was the most forceful and potent critic of DSM-5. In his high profile 
articles he argued that many changes were arbitrary and scientifically untenable and with the expansiveness of diagnos-
tic categories and diagnosis based on checklists of symptoms, would be more beneficial to drug companies than to the 
client themselves. He also bemoaned the fact that DSM’s descriptive and atheoretical approach was biased in favor of 
medication and downplayed the role of psychotherapy and counseling. While it is not possible to address all the conten-
tious changes in DSM-5, the elimination of bereavement exclusion from Major Depressive Disorder (MDD), increases 
the probability of diagnosing normal grief reaction as MDD. To be diagnosed with MDD if a person has 5 out of the 9 
symptoms (such as sadness, insomnia, difficulty in concentration and engaging in everyday activities etc.) which have 
persisted for more than 2 months, criteria of MDD has been met. The checklist of symptoms for MDD are similar to the 
anguish felt and observed in a person who has lost a loved one. In conclusion there is no denying that the DSM has 
provided psychiatrists with a common, agreed upon language which is indispensable if research has to keep pace with 
modern medicine. In lending clarity to the diagnosis of some major disorders the DSM has provided guidance to the 
diligent use of psychotropic medication. However, DSM with its ever- expanding list and confusing rearrangement of 
diagnostic categories has medicalized normal human emotions. In its quest to be scientific, it seems to have lost sight 
of the nature of psychological suffering, a construct that is fundamentally non-empirical.
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INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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PSYCHIATRIC DIAGNOSIS AND HUMAN EMOTIONS
( iii ) V O L .  1 0  ( 1 )  J A N   -   M A R C H   2 0 1 5P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
Psychiatry is a human science and its subject matter is the individual’s psychic reality which defies the degree of 
certainty and validity required of the discourse in natural sciences. However, modern psychiatry, as we know it, in the 
21st century has moved from understanding the psychogenic cause of a symptom to a medical model of controlling 
and manipulating symptoms. An important reason for this shift was the increasing awareness that some medications 
(lithium carbonate, antipsychotics, antidepressants, anxiolytics) were of benefit to certain kinds of disorders, and the 
ongoing research in this area held a promise for better and more effective medications that could target many other 
mental disorders. Equally important was the dissatisfaction and conflict within the profession, as well as the attacks, 
in the 1950’s, from the antipsychiatry movement that challenged the arbitrariness of psychiatric diagnosis which lacked 
a pathophysiologic explanation for the illness. An indication of the American Psychiatric Association’s (APA) struggle to 
develop a credible classification system of psychiatric disorders is best reflected in the history of the Diagnostic Statistical 
Manual (DSM). This manual was first published in 1952, with subsequent revisions, the latest being the publication of 
DSM-5, in 2013. Until the 1970’s the manuals (DSM-I and DSM-II) were conceived on a biopsychosocial model with 
a psychodynamic tilt influenced by Freud’s theory of personality development and intrapsychic conflict, as well as 
Meyer’s psychosocial model, which downplayed psychiatric disorders as discrete, specific pathological entities. This 
model had a significant impact in teaching and clinical practice with individual psychotherapy becoming an essential 
feature of psychiatry. However the shortcoming of this approach was that it lacked a clear demarcation between the 
mentally healthy and sick; this lead to questions about the status and legitimacy of psychiatry as a medical science. 
Added to the grave doubts about the validity and reliability of psychiatric diagnosis was the embarrassment when in the 
early 1970’s the gay rights movement lobbied against homosexuality being labeled as a disorder in DSM-II, which was 
later excluded from DSM III published in 1980. So the removal of a disorder was based on political pressure, rather 
than scientific research. DSM-III (followed by DSM-III- R, 1989) which was a significant turning point in the history of 
psychiatry in USA, adopted a descriptive, nosological approach which could be supported by research findings that lent 
greater reliability and validity to psychiatric constructs. Assessment through description of symptoms which were 
publicly visible was stressed over psychological etiology which by its very nature was private and invisible. This bold and 
creditable step by the APA was not free from criticisms, many of which were warranted. A most vocal critic of DSM-III-R, 
Dr. Paula Caplan a clinical and research psychologist, and a human rights advocate, forwarded a trenchant argument 
against the inclusion of diagnostic labels, such as Self-Defeating Personality Disorder (SDPD) and Premenstrual 
Dysphoric Disorder (PMDD). Both these disorders were applicable to a majority of women. The former (SDPD), 
facetiously referred to as “good wife syndrome”, included characteristics such a putting needs of others ahead of one’s 
own, feeling unappreciated etc. Interestingly, this “portrait” of SDPD is most germane to the accepted and desirable 
gender role for Pakistani women as well. The latter’s (PMDD) diagnostic features consist of “bloating” breast tender-
ness coupled with irritability, fatigue, being “on edge” etc. Dr. Caplan questioned the scientific basis of inclusion of 
PMDD in a psychiatric manual, pointing out that it is just a fancy name for PMS. In lieu of the scathing criticism from 
feminists, the two diagnoses were not included in the main text of DSM-III-R and DSM-IV-TM (2004) but were instead 
placed in an appendix titled “Diagnostic Categories Needing Further Study.” The publication of DSM-5 in 2013, nine 
years after DSM-IV-TM was awaited with much anticipation. Surprisingly, mental health professionals expressed 
concerns while DSM-5 was in the making. Most of these concerns were around newly introduced categories and the 
lowering of thresholds for many disorders which would invariably lead to over diagnosis of the existing disorders. Allen 
Frances, who chaired the task force of DSM-IV was the most forceful and potent critic of DSM-5. In his high profile 
articles he argued that many changes were arbitrary and scientifically untenable and with the expansiveness of diagnos-
tic categories and diagnosis based on checklists of symptoms, would be more beneficial to drug companies than to the 
client themselves. He also bemoaned the fact that DSM’s descriptive and atheoretical approach was biased in favor of 
medication and downplayed the role of psychotherapy and counseling. While it is not possible to address all the conten-
tious changes in DSM-5, the elimination of bereavement exclusion from Major Depressive Disorder (MDD), increases 
the probability of diagnosing normal grief reaction as MDD. To be diagnosed with MDD if a person has 5 out of the 9 
symptoms (such as sadness, insomnia, difficulty in concentration and engaging in everyday activities etc.) which have 
persisted for more than 2 months, criteria of MDD has been met. The checklist of symptoms for MDD are similar to the 
anguish felt and observed in a person who has lost a loved one. In conclusion there is no denying that the DSM has 
provided psychiatrists with a common, agreed upon language which is indispensable if research has to keep pace with 
modern medicine. In lending clarity to the diagnosis of some major disorders the DSM has provided guidance to the 
diligent use of psychotropic medication. However, DSM with its ever- expanding list and confusing rearrangement of 
diagnostic categories has medicalized normal human emotions. In its quest to be scientific, it seems to have lost sight 
of the nature of psychological suffering, a construct that is fundamentally non-empirical.
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INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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